Skip to contentpdufa.bio

pitolisant HD (high-dose)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

pitolisant HD (high-dose) is a Harmony Biosciences Holdings, Inc. program in narcolepsy and idiopathic hypersomnia. Its next catalyst is a Readout in Q4 2027.

HRMY catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: narcolepsy and idiopathic hypersomnia. Sponsor: Harmony Biosciences Holdings, Inc. (HRMY). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027HRMY

Questions

When is pitolisant HD (high-dose)'s next FDA decision or readout?

The next tracked catalyst for pitolisant HD (high-dose) is a Readout in Q4 2027.

What happened at pitolisant HD (high-dose)'s most recent FDA decision?

No FDA decision for pitolisant HD (high-dose) is in our archive yet.

What is pitolisant HD (high-dose) used for?

In our records pitolisant HD (high-dose) is under review or in development for narcolepsy and idiopathic hypersomnia.

Who makes pitolisant HD (high-dose)?

Harmony Biosciences Holdings, Inc. (HRMY).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.